Inflammation, fibrosis, and modulation of the process by mesenchymal stem/stromal cells

Matrix Biology

Volumn 51, Issue , 2016, Pages 7-13

  Prockop, Darwin J ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Mesenchymal stem stromal cells; Regenerative medicine; Tissue fibrosis; TSG 6

Indexed keywords

BIOLOGICAL MARKER; DAMAGE ASSOCIATED MOLECULAR PATTERN; HYDROXYPROLINE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROCOLLAGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME; PROTEIN; TUMOR NECROSIS FACTOR ALPHA STIMULATED PROTEIN 6; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; COLLAGEN; TNFAIP6 PROTEIN, HUMAN;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLOGRAFT; ANTIINFLAMMATORY ACTIVITY; ARTERIAL OXYGEN SATURATION; CELL DIFFERENTIATION; COLLAGEN FIBER; COLLAGEN SYNTHESIS; DENDRITIC CELL; FIBROSIS; GENE MUTATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HEMATOPOIETIC STEM CELL; HUMAN; HYDROXYLATION; INFLAMMATION; MACROPHAGE; MAST CELL; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; NONHUMAN; OSTEOARTHRITIS; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCAR FORMATION; BIOLOGICAL THERAPY; GENETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; PATHOLOGY; PROCEDURES; REGENERATION; SCAR;

CELL ADHESION MOLECULES; CELL- AND TISSUE-BASED THERAPY; CICATRIX; COLLAGEN; FIBROSIS; HUMANS; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; REGENERATION;

EID: 84959218206     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.01.010     Document Type: Review

References (44)

1. Rosenbloom J., Prockop D.J. Incorporation of cis-hydroxyproline into protocollagen and collagen. Collagen containing cis-hydroxyproline in place of proline and trans-hydroxyproline is not extruded at a normal rate. J. Biol. Chem. 1971, 246:1549-1555.
2. Uitto J., Hoffman H., Prockop D.J. Retention of nonhelical procollagen containing cis-hydroxyproline in rough endoplasmic reticulum. Science 1975, 190:1202-1204.
3. Jimenez S.A., Ala-Kokko L., Ahmad N., Baldwin C., Dharmavaram R., Reginato A., Knowlton R., Prockop D.J. Type II collagen gene mutations in familial osteoarthritis. Articular Cartilage and Osteoarthritis 1992, 167-178. Raven Press Ltd., New York. K. al. (Ed.).
4. Prockop D.J., Kivirikko K.I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. 1995, 64:403-434.
5. Prockop D.J., Bateman J. Heritable disorders of connective tissues. Harrison's Principles of Internal Medicine 2014, McGraw Hill Medical, New York. 19th ed. L. Jameson (Ed.).
6. Laitala A., Aro E., Walkinshaw G., Maki J.M., Rossi M., Heikkila M., Savolainen E.R., Arend M., Kivirikko K.I., Koivunen P., Myllyharju J. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood 2012, 120:3336-3344.
7. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
8. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 1991, 9:641-650.
9. Pereira R.F., O'Hara M.D., Laptev A.V., Halford K.W., Pollard M.D., Class R., Simon D., Livezey K., Prockop D.J. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1142-1147.
10. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., Sussman M., Orchard P., Marx J.C., Pyeritz R.E., Brenner M.K. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 1999, 5:309-313.
11. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
12. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
13. Prockop D.J., Kota D.J., Bazhanov N., Reger R.L. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J. Cell. Mol. Med. 2010, 14:2190-2199.
14. Sharma R.R., Pollock K., Hubel A., McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion (Paris) 2014, 54:1418-1437.
15. Prockop D.J., Keating A. Relearning the lessons of genomic stability of human cells during expansion in culture: implications for clinical research. Stem Cells 2012, 30:1051-1052.
16. Kfoury Y., Scadden D.T. Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell 2015, 16:239-253.
17. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol. Ther. 2012, 20:14-20.
18. Munoz J.R., Stoutenger B.R., Robinson A.P., Spees J.L., Prockop D.J. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18171-18176.
19. Penfornis P., Vallabhaneni K.C., Whitt J., Pochampally R. Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment. Int. J. Cancer 2015.
20. Heldring N., Mager I., Wood M.J., Le Blanc K., Andaloussi S.E. Therapeutic potential of multipotent mesenchymal stromal cells and their extracellular vesicles. Hum. Gene Ther. 2015.
21. Spees J.L., Olson S.D., Whitney M.J., Prockop D.J. Mitochondrial transfer between cells can rescue aerobic respiration. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1283-1288.
22. Islam M.N., Das S.R., Emin M.T., Wei M., Sun L., Westphalen K., Rowlands D.J., Quadri S.K., Bhattacharya S., Bhattacharya J. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat. Med. 2012, 18:759-765.
23. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 2004, 95:9-20.
24. Iso Y., Spees J.L., Serrano C., Bakondi B., Pochampally R., Song Y.H., Sobel B.E., Delafontaine P., Prockop D.J. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem. Biophys. Res. Commun. 2007, 354:700-706.
25. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., Semprun-Prieto L., Delafontaine P., Prockop D.J. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
26. Milner C.M., Higman V.A., Day A.J. TSG-6: a pluripotent inflammatory mediator?. Biochem. Soc. Trans. 2006, 34:446-450.
27. Wisniewski H.G., Vilcek J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Cytokine Growth Factor Rev. 2004, 15:129-146.
28. Oh J.Y., Roddy G.W., Choi H., Lee R.H., Ylostalo J.H., Rosa R.H., Prockop D.J. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16875-16880.
29. Choi H., Lee R.H., Bazhanov N., Oh J.Y., Prockop D.J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 2011, 118:330-338.
30. Foskett A.M., Bazhanov N., Ti X., Tiblow A., Bartosh T.J., Prockop D.J. Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 306:L120-L131.
31. Oh J.Y., Lee R.H., Yu J.M., Ko J.H., Lee H.J., Ko A.Y., Roddy G.W., Prockop D.J. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol. Ther. 2012, 20:2143-2152.
32. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010, 140:771-776.
33. Headland S.E., Norling L.V. The resolution of inflammation: principles and challenges. Semin. Immunol. 2015, 27:149-160.
34. Colter D.C., Class R., DiGirolamo C.M., Prockop D.J. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3213-3218.
35. Sekiya I., Larson B.L., Smith J.R., Pochampally R., Cui J.G., Prockop D.J. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002, 20:530-541.
36. Liu Y., Munoz N., Bunnell B.A., Logan T.M., Ma T. Density-dependent metabolic heterogeneity in human mesenchymal stem cells. Stem Cells 2015.
37. Kim D.S., Lee M.W., Yoo K.H., Lee T.H., Kim H.J., Jang I.K., Chun Y.H., Park S.J., Lee S.H., Son M.H., Jung H.L., Sung K.W., Koo H.H. Gene expression profiles of human adipose tissue-derived mesenchymal stem cells are modified by cell culture density. PLoS One 2014, 9.
38. Lee M.W., Kim D.S., Yoo K.H., Kim H.R., Jang I.K., Lee J.H., Kim S.Y., Son M.H., Lee S.H., Jung H.L., Sung K.W., Koo H.H. Human bone marrow-derived mesenchymal stem cell gene expression patterns vary with culture conditions. Blood Res. 2013, 48:107-114.
39. Mareschi K., Rustichelli D., Calabrese R., Gunetti M., Sanavio F., Castiglia S., Risso A., Ferrero I., Tarella C., Fagioli F. Multipotent mesenchymal stromal stem cell expansion by plating whole bone marrow at a low cellular density: a more advantageous method for clinical use. Stem Cells Int. 2012, 2012:920581.
40. Yoon D.S., Kim Y.H., Jung H.S., Paik S., Lee J.W. Importance of Sox2 in maintenance of cell proliferation and multipotency of mesenchymal stem cells in low-density culture. Cell Prolif. 2011, 44:428-440.
41. Cholewa D., Stiehl T., Schellenberg A., Bokermann G., Joussen S., Koch C., Walenda T., Pallua N., Marciniak-Czochra A., Suschek C.V., Wagner W. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant. 2011, 20:1409-1422.
42. Wilson J.G., Liu K.D., Zhuo H., Caballero L., McMillan M., Fang X., Cosgrove K., Vojnik R., Calfee C.S., Lee J.W., Rogers A.J., Levitt J., Wiener-Kronish J., Bajwa E.K., Leavitt A., McKenna D., Thompson B.T., Matthay M.A. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir. Med. 2015, 3:24-32.
43. Trounson A., McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 2015, 17:11-22.
44. Lee R.H., Yu J.M., Foskett A.M., Peltier G., Reneau J.C., Bazhanov N., Oh J.Y., Prockop D.J. TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:16766-16771.